News
Stay up to date on the latest company news:
4 November 2025
羞羞视频 to Present Preclinical Data Highlighting Potent, Synergistic Effects of ABX-001 in Combination with Bispecific T-cell Engagers at SITC 2025
23 October 2025
羞羞视频 Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
14 October 2025
羞羞视频 Publishes in Cell Reports Medicine Validating ABX-001's Potential to Overcome Cancer Immunotherapy Hurdles
09 October 2024
羞羞视频 Appoints Gerben Moolhuizen as Chief Executive Officer
18 March 2024
羞羞视频 selected for funding project by KMU-innovativ, an initiative from Germany鈥榮 Federal Ministry of Education and Research (BMBF)
18 October 2022
羞羞视频 Appoints Thomas Bogenrieder as Chief Medical Officer
12 August 2022
羞羞视频---arenaviruses take on cancer
14 October 2021
羞羞视频 Completes Series A Extension Bringing Total Raised to EUR 43 Million
05 February 2020
羞羞视频 Expands Leadership Team with Drug Development and Viral Therapy Manufacturing Experts
15 October 2019
羞羞视频 Launches with 鈧�12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer
Events
Want to get in touch with the 羞羞视频 Team? Meet us at the following events:
November 19-20, 2025
Contract Manufacturing Europe 2025
Location: Munich, Germany
Participant: Dethardt M眉ller, CTO
Presentation: Balancing Safety, Efficacy and Cost Considerations in the Clinical Manufacturing of Arenavirus-Based Cancer Immunotherapies.
December 1-3, 2025
Cell & Gene Therapy International Europe 2025
Location: Berlin, Germany
Participant: Dethardt M眉ller, CTO
February 10-12, 2026
IO360掳 Summit 2026
Location: Boston, USA
Participant: Gerben Moolhuizen, CEO